Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Prospective Phase II Trial of a Combination of Gemcitabine and UFT as First-Line Treatment in Elderly Patients With Advanced Non-Small Cell Carcinoma

Authors not listed

Ulsan University Hospital · 2008

Abstract

Cares for elderly patients with advanced non-small cell lung cancer(NSCLC) become one of the common clinical practices oncologist are now facing. So, we need to seek adequate regimens for them. Gemcitabine is well known to be one of active third generation agents in terms of both efficacy and tolerability. Gemcitabine alone have been recommended as first line treatment for elderly NSCLC patients, especially in the aspect of tolerability. However, gemcitabine alone is suggested to be suboptimal to control their disease. Therefore, we plan to make an optimal regimen containing gemcitabine for the elderly patients.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-01 MST

Cite this

APA
Anonymous. (2008). Prospective Phase II Trial of a Combination of Gemcitabine and UFT as First-Line Treatment in Elderly Patients With Advanced Non-Small Cell Carcinoma. <em>Ulsan University Hospital</em>. https://clinicaltrials.gov/study/NCT00625352
Vancouver
Anonymous. Prospective Phase II Trial of a Combination of Gemcitabine and UFT as First-Line Treatment in Elderly Patients With Advanced Non-Small Cell Carcinoma. Ulsan University Hospital. 2008.
BibTeX
@misc{anon2008Prospe, title = {Prospective Phase II Trial of a Combination of Gemcitabine and UFT as First-Line Treatment in Elderly Patients With Advanced Non-Small Cell Carcinoma}, author = {Anonymous}, journal = {Ulsan University Hospital}, year = {2008}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings